Search





Search





Markets
/
Stocks
/
dnli
/

Denali Therapeutics Inc

DNLI

Add to Watchlist

24.040USD

+0.470+1.99%

Close 07-27 16:00（ET）Quotes delayed by 15 min

3.81BMarket Cap

LossP/E TTM

Denali Therapeutics Inc

24.040

+0.470+1.99%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+1.99%

5 Days

+4.98%

1 Month

-5.98%

6 Months

+15.36%

Year to Date

+45.61%

1 Year

+75.86%

Key Figures

23.920Open

24.055High

2.11MVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

1.33%Turnover Ratio

23.570Prev. Close

23.150Low

32.91MTurnover

LossP/E Static

4.12P/B

0.00%Div Yield TTM

-40.04%ROA

23.77052wk High

1.63Volume Ratio

-422.77MNet Profit

158.66MShares

-2.8803EPS TTM

1.02Beta

-49.59%ROE

12.58052wk Low

3.84%Amplitude

100.00%Gross Margin

3.81BMarket Cap

-2.66Reward/Risk

3.37%Risk Rate

TradingKey Stock Score of Denali Therapeutics Inc

Currency: USD Updated: 2026-07-27

Key Insights

Denali Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 70 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.67.In the medium term, the stock price is expected to trend up.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Denali Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

70 / 386

Overall Ranking

145 / 4282

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Denali Therapeutics Inc Highlights

StrengthsRisks

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -8.18, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 158.73M shares, increasing 0.58% quarter-over-quarter.

Held by Bill Nygren | OAKMX

Star Investor Bill Nygren | OAKMX holds 61.85K shares of this stock.